AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT
Tóm tắt
Segmenting the whole-body somatostatin receptor-expressing tumour volume (SRETVwb) on positron emission tomography/computed tomography (PET/CT) images is highly time-consuming but has shown value as an independent prognostic factor for survival. An automatic method to measure SRETVwb could improve disease status assessment and provide a tool for prognostication. This study aimed to develop an artificial intelligence (AI)-based method to detect and quantify SRETVwb and total lesion somatostatin receptor expression (TLSREwb) from [68Ga]Ga-DOTA-TOC/TATE PET/CT images.
A UNet3D convolutional neural network (CNN) was used to train an AI model with [68Ga]Ga-DOTA-TOC/TATE PET/CT images, where all tumours were manually segmented with a semi-automatic method. The training set consisted of 148 patients, of which 108 had PET-positive tumours. The test group consisted of 30 patients, of which 25 had PET-positive tumours. Two physicians segmented tumours in the test group for comparison with the AI model. There were good correlations between the segmented SRETVwb and TLSREwb by the AI model and the physicians, with Spearman rank correlation coefficients of r = 0.78 and r = 0.73, respectively, for SRETVwb and r = 0.83 and r = 0.81, respectively, for TLSREwb. The sensitivity on a lesion detection level was 80% and 79%, and the positive predictive value was 83% and 84% when comparing the AI model with the two physicians. It was possible to develop an AI model to segment SRETVwb and TLSREwb with high performance. A fully automated method makes quantification of tumour burden achievable and has the potential to be more widely used when assessing PET/CT images.
Tài liệu tham khảo
Abdulrezzak U, Kurt YK, Kula M, Tutus A (2016) Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun 37(8):874
Alzubaidi L, Zhang J, Humaidi AJ, Al-Dujaili A, Duan Y, Al-Shamma O et al (2021) Review of deep learning: concepts, CNN architectures, challenges, applications, future directions. J Big Data 8(1):53
Beauregard JM, Hofman MS, Kong G, Hicks RJ (2012) The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 39(1):50–56
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44(9):1588–1601
Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D et al (2010) Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med off Publ Soc Nucl Med 51(3):353–359
Carlsen EA, Johnbeck CB, Loft M, Pfeifer A, Oturai P, Langer SW et al (2021) Semiautomatic tumor delineation for evaluation of (64)Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume. J Nucl Med off Publ Soc Nucl Med 62(11):1564–1570
Carlsen EA, Lindholm K, Hindsholm A, Gæde M, Ladefoged CN, Loft M et al (2022) A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms. EJNMMI Res 12(1):30
Chan YH (2003) Biostatistics 104: correlational analysis. Singap Med J 44(12):614–619
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A et al (2017) Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics 7(5):1149–1158
Chen L, Jumai N, He Q, Liu M, Lin Y, Luo Y et al (2023) The role of quantitative tumor burden based on [68Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis. Eur J Nucl Med Mol Imaging 50(2):525–534
Courville IJGaYBaA (2016) Deep learning. MIT Press, Cambridge
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335–1342
Ebbers SC, Heimgartner M, Barentsz MW, van Leeuwaarde RS, van Treijen MJC, Lam MMEG et al (2021) Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. Eur J Hybrid Imaging 5(1):22
Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M et al (2017) 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients. J Nucl Med off Publ Soc Nucl Med 58(2):307–311
Foster B, Bagci U, Mansoor A, Xu Z, Mollura DJ (2014) A review on segmentation of positron emission tomography images. Comput Biol Med 50:76–96
Gålne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenström E et al (2019) A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors. J Nucl Med 60(12):1717–1723
Goodfellow IBY, Courville A (2016) Deep learning. MIT Press
Hastie T, Tibshirani R, Friedman J (2001) The elements of statistical learning. Springer New York Inc, New York
Im HJ, Bradshaw T, Solaiyappan M, Cho SY (2018) Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging 52(1):5–15
Kaderli RM, Spanjol M, Kollár A, Bütikofer L, Gloy V, Dumont RA et al (2019) Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis. JAMA Oncol 5(4):480–489
Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A et al (2015) SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 17(3):313–318
Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WA (2012) Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem 23(8):1712–1717
Pantelis AG, Panagopoulou PA, Lapatsanis DP (2022) Artificial intelligence and machine learning in the diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms-A scoping review. Diagnostics (basel) 12(4):874
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G et al (2011) 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 52(12):1864–1870
Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24(4):389–427
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273–282
Thuillier P, Liberini V, Grimaldi S, Rampado O, Gallio E, Santi BD et al (2022) Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC PET/CT in well-differentiated neuroendocrine tumors. J Nucl Med 63(7):1014–1020
Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K et al (2017) Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (68)Ga-DOTATATE-Avid tumor volume measurements. Eur J Endocrinol 176(5):575–582
Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G et al (2019) Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging 46(11):2244–2251
Trägårdh E, Borrelli P, Kaboteh R, Gillberg T, Ulén J, Enqvist O et al (2020) RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology. EJNMMI Phys 7(1):51
Trägårdh E, Enqvist O, Ulén J, Jögi J, Bitzén U, Hedeer F et al (2022) Freely available, fully automated AI-based analysis of primary tumour and metastases of prostate cancer in whole-body [(18)F]-PSMA-1007 PET-CT. Diagnostics (basel) 12(9):2101
Velikyan I, Sundin A, Sorensen J, Lubberink M, Sandstrom M, Garske-Roman U et al (2014) Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med 55(2):204–210
Wehrend J, Silosky M, Xing F, Chin BB (2021) Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network. EJNMMI Res 11(1):98
WHO Classification of Tumours Editorial Board (2019) Digestive system tumors. International Agency for Research on Cancer, Lyon
Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA et al (2007) Processing of generator-produced 68Ga for medical application. J Nucl Med off Publ Soc Nucl Med 48(10):1741–1748